Cardiology Department, Hospital Universitari de Bellvitge (IDIBELL) & CIBERCV, 08907, L'Hospitalet de Llobregat, Spain.
Health Economics & Outcomes Research, Atrys Health, 28002, Madrid, Spain.
J Comp Eff Res. 2023 Aug;12(8):e230007. doi: 10.57264/cer-2023-0007. Epub 2023 Jul 25.
Healthcare resources usage and costs associated to nonvalvular atrial fibrillation (NVAF) were analyzed in Spain. This is an observational and retrospective study on patients with NVAF who started their treatment with apixaban or acenocoumarol between 1 January 2015 and 31 December 2017. 2160 patients treated with apixaban were paired (1:1) with patients treated with acenocoumarol (propensity score matching). Apixaban reduced the incidence of strokes and systemic embolisms, minor and major bleedings and deaths, versus acenocoumarol. Apixaban led to reductions of 80, 55 and 43% in costs related to nursing visits, hospitalizations, and emergency visits, respectively, leading to annual cost savings of €274/patient, from the perspective of society. Our results suggested that apixaban is a cost-effective alternative for patients with NVAF.
本研究旨在分析西班牙非瓣膜性心房颤动（NVAF）患者的医疗资源使用情况和相关成本。这是一项观察性、回顾性研究，共纳入了 2160 例于 2015 年 1 月 1 日至 2017 年 12 月 31 日期间开始服用阿哌沙班或华法林的 NVAF 患者，将服用阿哌沙班的患者与服用华法林的患者进行 1:1 倾向性评分匹配。与华法林相比，阿哌沙班可降低卒中和全身性栓塞、轻微和严重出血以及死亡的发生率。从社会角度来看，阿哌沙班可分别降低与护理就诊、住院和急诊就诊相关的成本 80%、55%和 43%，每年可为每位患者节省 274 欧元。研究结果表明，阿哌沙班是 NVAF 患者的一种具有成本效益的替代治疗选择。
